Century Therapeutics

Please note: The information displayed on this page might be outdated.
Century Therapeutics: Developer of allogeneic living drugs designed to overcome the limitations of first-generation cell therapies. The company's drugs are genetically-engineered, iPSC-derived immune effector cell products designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, enabling patients to have access to curative therapies for cancer.

Company Status (as of 2019-07-01):
The company raised $250 million of venture funding in a deal led by Leaps by Bayer on July 1, 2019. Cellular Dynamics International and Versant Venture Management also participated in the round. The funds will be used to advance multiple programs into the clinic for hematologic and solid malignancies.
Based in...
US - Middle Atlantic
Clinical Stage
Pre-Clinical Stage
Disease Space
Central Nervous System, Oncology
3601 Market St
Philadelphia, PA 19104
United States

Company Participants at Winter Private Company Showcase

Lalo Flores
Century Therapeutics, Chief Executive Officer & Board Member
Lalo Flores is Chief Executive Officer of Century Therapeutics. He was previously Vice President of R&D and Entrepreneur-in-Residence with Janssen (Johnson & Johnson). He assumed those roles after completing the acquisition and integration of Novira Therapeutics, where he was a co-founder, the President and Chief Scientific Officer. Prior to Novira, Lalo was a department head at Merck & Co., where he led drug discovery and development programs across diverse therapeutic areas including antiviral, oncology and metabolic. He started his R&D career at Tularik Inc., establishing key elements of the antiviral drug discovery platform. Lalo received his PhD in Biochemistry and Molecular Biology from Rutgers University and was a postdoctoral Fellow at the Salk Institute.

Upcoming Company Event Participation